Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2024

Open Access 01-12-2024 | Obesity | Research

The economic burden of obesity in 4 south-eastern European countries associated with obesity-related co-morbidities

Authors: Kostas Athanasakis, Cornelia Bala, Alexander Kokkinos, Gabor Simonyi, Klaudia Hálová Karoliová, Amaury Basse, Miodrag Bogdanovic, Malvin Kang, Kaywei Low, Adrien Gras

Published in: BMC Health Services Research | Issue 1/2024

Login to get access

Abstract

Objective

To provide an assessment of the cost burden of obesity across a spectrum of obesity-related comorbidities (ORCs) for four countries in South-Eastern Europe (SEE).

Methods

A micro-costing analysis from the public payer perspective was conducted to estimate direct healthcare costs associated with ten obesity-related comorbidities (ORCs) in Czech Republic, Greece, Hungary, and Romania. A survey was administered to obtain healthcare resource use and unit cost data. Cost estimates were validated by local steering committees which comprised at least one public sector clinician and a panel of independent industry experts.

Results

Chronic kidney disease and cardiovascular diseases were the costliest ORCs across all 4 countries, where annual cost burden per ORC exceeded 1,500 USD per patient per year. In general, costs were driven by the tertiary care resources allocated to address treatment-related adverse events, disease complications, and associated inpatient procedures.

Conclusions

Our findings confirm that the high prevalence of obesity and its comorbidities result in substantial financial burden to all 4 SEE public payers. By quantifying the burden of obesity from a public healthcare perspective, our study aims to support policy efforts that promote health education and promotion in combating obesity in the region.
Appendix
Available only for authorised users
Literature
1.
World Obesity Atlas. 2023; World Obesity Federation: March 2023, 2023.
2.
Obesity. Missing the 2025 global targets; World Obesity Foundation: March 2020, 2020; pp 1-242.
3.
Malnick SDH, Knobler H. The medical complications of obesity. QJM: Int J Med. 2006;99(9):565–79.CrossRef
4.
5.
Gallus S, Lugo A, Murisic B, Bosetti C, Boffetta P, La Vecchia C. Overweight and obesity in 16 European countries. Eur J Nutr. 2015;54(5):679–89.CrossRefPubMed
6.
Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries, 2014. Eur J Pub Health. 2017;28(2):295–300.CrossRef
7.
Stival C, Lugo A, Odone A, van den Brandt PA, Fernandez E, Tigova O, Soriano JB, José López M, Scaglioni S, Gallus S. Prevalence and correlates of overweight and obesity in 12 European countries in 2017–2018. Obes Facts. 2022;15(5):655–65.CrossRefPubMedPubMedCentral
8.
World Health Organization. Regional Office for, E., WHO European Regional Obesity Report 2022. World Health Organization. Regional Office for Europe: Copenhagen, 2022.
9.
Ponce-Garcia I, Simarro-Rueda M, Carbayo-Herencia JA, Divisón-Garrote JA, Artigao-Ródenas LM, Botella-Romero F, Palazón-Bru A, Martínez-St. John DRJ, Gil-Guillén VF, Geva. Prognostic Value of Obesity on both overall mortality and Cardiovascular Disease in the General Population. PLoS ONE. 2015;10(5):e0127369.CrossRefPubMedPubMedCentral
10.
Touloumi G, Karakosta A, Kalpourtzi N, Gavana M, Vantarakis A, Kantzanou M, Hajichristodoulou C, Chlouverakis G, Trypsianis G, Voulgari PV, Alamanos Y, Makrilakis K, Liatis S, Chatzipanagiotou S, Stergiou G, Yannis A, Alexis B, Grigoris C, Christos H, Anna K, George S, Giota T, Grigoris T, Apostolos V, Paraskevi V, Argiro K, Nikos P, Georgia V, Natasa K, Klea K, Maria K, Xenia C, Magda G, Bettina H, Christos H, George R, Paraskevi VV, Ilias N, Koustenis P, Konstantinos M, Stavros L. High prevalence of cardiovascular risk factors in adults living in Greece: the EMENO National Health Examination Survey. BMC Public Health. 2020;20(1):1665. on behalf of the, E. s. g.CrossRefPubMedPubMedCentral
11.
Vlad T, Berbecar GI, Mircescu G. Prevalence of hypertension and cardiovascular disease in the rural population: results from the Romanian mobile health caravans. J Community Med Public Health Rep. 2021;2:9.
12.
Lu W, Pikhart H, Tamosiunas A, Kubinova R, Capkova N, Malyutina S, Pająk A, Bobak M. Prevalence, awareness, treatment and control of hypertension, diabetes and hypercholesterolemia, and associated risk factors in the Czech Republic, Russia, Poland and Lithuania: a cross-sectional study. BMC Public Health. 2022;22(1):883.CrossRefPubMedPubMedCentral
13.
14.
Iski G, Rurik I. The estimated economic burden of overweight and obesity in Hungary. Orv Hetil. 2014;155(35):1406–12.CrossRefPubMed
15.
Klarenbach S, Padwal R, Chuck A, Jacobs P. Population-Based Anal Obes Workforce Participation Obes. 2006;14(5):920–7.
16.
Knai C, Suhrcke M, Lobstein T. Obesity in Eastern Europe: an overview of its health and economic implications. Econ Hum Biology. 2007;5(3):392–408.CrossRef
17.
Landovská P, Karbanová M. Social costs of obesity in the Czech Republic. The European Journal of Health Economics; 2022.
18.
Müller-Riemenschneider F, Reinhold T, Berghöfer A, Willich SN. Health-economic burden of obesity in Europe. Eur J Epidemiol. 2008;23(8):499.CrossRefPubMed
19.
Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. 2022, 7 (9), e009773.
20.
Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes. 2021;45(6):1249–58.CrossRef
21.
Chapel JM, Wang G. Understanding cost data collection tools to improve economic evaluations of health interventions. 2019, 4 (4), 214–222.
22.
Špacírová Z, Epstein D, García-Mochón L, Rovira J, Olry de Labry Lima A, Espín J. A general framework for classifying costing methods for economic evaluation of health care. Eur J Health Econ. 2020;21(4):529–42.CrossRefPubMedPubMedCentral
23.
Drummond MF, Claxton SM, Stoddart K, Torrance GL. GW., Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; 2015.
24.
Alqahtani SA, Al-Omar HA, Alshehri A, Abanumay A, Alabdulkarim H, Alrumaih A, Eldin MS, Schnecke V. Obesity Burden and Impact of Weight loss in Saudi Arabia: a modelling study. Advances in Therapy; 2023.
25.
26.
27.
28.
Dalal JJ, Padmanabhan TNC, Jain P, Patil S, Vasnawala H, Gulati A. LIPITENSION: Interplay between dyslipidemia and hypertension. 2012, 16 (2), 240–5.
29.
Miao J, Zang X, Cui X, Zhang J. Autophagy, Hyperlipidemia, and atherosclerosis. In: Le W, editor. Autophagy: Biology and diseases: clinical science. Springer Singapore: Singapore,; 2020. pp. 237–64.
30.
Pollevick ME, Xu KY, Mhango G, Federmann EG, Vedanthan R, Busse P, Holguin F, Federman AD, Wisnivesky JP. The Relationship between Asthma and Cardiovascular Disease: an examination of the Framingham offspring study. CHEST 2021, 159 (4), 1338–45.
31.
Tattersall MC, Guo M, Korcarz CE, Gepner AD, Kaufman JD, Liu KJ, Barr RG, Donohue KM, McClelland RL, Delaney JA, Stein JH. Asthma Predicts Cardiovasc Disease Events. 2015;35(6):1520–5.
32.
Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018;18(1):975.CrossRefPubMedPubMedCentral
33.
Ferrara P, Di Laura D, Cortesi PA, Mantovani LG. The economic impact of hypercholesterolemia and mixed dyslipidemia: a systematic review of cost of illness studies. PLoS ONE 2021, 16 (7), e0254631.
34.
Mohamed-Yassin M-S, Baharudin N, Abdul-Razak S, Ramli AS, Lai NM. Global prevalence of dyslipidaemia in adult populations: a systematic review protocol. 2021, 11 (12), e049662.
35.
Mikhail V, Ionov NEZ, Alexandra O, Konradi. Status of hypertension in Russia and Eastern Europe. Eur Soc Cardiol. 2019;17:24.
36.
Stel VS, de Jong RW, Kramer A, Andrusev AM, Baltar JM, Barbullushi M, Bell S, de la Castro P, Cernevskis H, Couchoud C, De Meester J, Eriksen BO, Gârneaţă L, Golan E, Helve J, Hemmelder MH, Hommel K, Ioannou K, Jarraya F, Kantaria N, Kerschbaum J, Komissarov KS, Magaz Á, Mercadal L, Ots-Rosenberg M, Pálsson R, Rahmel A, Rydell H, Savino M, Seyahi N, Slon Roblero MF, Stojceva-Taneva O, van der Tol A, Vazelov ES, Ziginskiene E, Zurriaga Ó, Vanholder RC, Massy ZA, Jager KJ. Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe. Kidney Int. 2021;100(1):182–95.CrossRefPubMed
37.
Niki Kalavrezou HJ. Healthcare Reform in Greece: Progress and Reform Priorities. 2021.
38.
Escobar C, Palacios B, Aranda U, Capel M, Sicras A, Sicras A, Hormigo A, Alcázar R, Manito N, Botana M. Costs and healthcare utilisation of patients with chronic kidney disease in Spain. BMC Health Serv Res. 2021;21(1):536.CrossRefPubMedPubMedCentral
39.
Czech M, Opolski G, Zdrojewski T, Dubiel JS, Wizner B, Bolisęga D, Fedyk-Łukasik M, Grodzicki T. The costs of heart failure in Poland from the public payer’s perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of car. Kardiologia Polska (Polish Heart Journal). 2013;71(3):224–32.CrossRefPubMed
40.
Fiorentino F, Ascenção R, Gouveia M, Costa J, Broeiro P, Fonseca C, Borges M. The cost of illness of heart failure in Portugal. Value Health. 2017;20(9):A610.CrossRef
41.
Sassi F, Hurst J. The Prevention of Lifestyle-Related Chronic Diseases. 2008.
42.
Gmeinder M, Morgan D, Mueller M. How much do OECD countries spend on prevention? 2017.
43.
Frick KD. Microcosting Quantity Data Collection Methods. 2009, 47 (7_Supplement_1), S76-S81.
44.
45.
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88.CrossRefPubMedPubMedCentral
Metadata
Title
The economic burden of obesity in 4 south-eastern European countries associated with obesity-related co-morbidities
Authors
Kostas Athanasakis
Cornelia Bala
Alexander Kokkinos
Gabor Simonyi
Klaudia Hálová Karoliová
Amaury Basse
Miodrag Bogdanovic
Malvin Kang
Kaywei Low
Adrien Gras
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2024
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-024-10840-4

Other articles of this Issue 1/2024

BMC Health Services Research 1/2024 Go to the issue

Research

The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews

Research

Medical specialists’ use and opinion of video consultation in Denmark: a survey study

Research

Attachment styles and healthcare utilization: exploring the role of the patient-doctor relationship

Research

Stakeholder opinions on perceived sub-standard emergency obstetric and newborn care in Ghana

Research

Newborn and child health national and provincial clinical practice guidelines in South Africa, Nigeria and Malawi: a scoping review

Systematic Review

Systematic review on the frequency and quality of reporting patient and public involvement in patient safety research